Abcam, ab21193, Anti-UBE2I / UBC9 antibody

Size: 100µg
Goat Polyclonal UBE2I / UBC9 antibody. Suitable for WB, IHC-P and reacts with Rat, Human samples. Cited in 20 publications. Immunogen corresponding to Synthetic Peptide within Human UBE2I aa 1-50.
Key facts
Host species:Goat,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Rat, Human,
Applications:IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Synthetic Peptide within Human UBE2I aa 1-50. The exact immunogen used to generate this antibody is proprietary information.P63279

Product details:
Product is very sensitive to freeze/thawing therefore this should be avoided. Store at 4C for short term use and -20C for long term storage in small aliquots.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Storage buffer-pH: 7.3Preservative: 0.02% Sodium azideConstituents: Tris buffered saline, 0.5% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
UBE2I also known as UBC9 is a small ubiquitin-related modifier (SUMO) conjugating enzyme. It plays an important role in the SUMOylation process which modifies proteins by attaching sumo proteins to them altering their function. This protein has a molecular mass of approximately 18 kDa. UBE2I is expressed broadly across various tissues demonstrating its significance in cellular processes.
Biological function summary
The SUMO conjugating enzyme UBE2I is part of the SUMOylation complex which includes the SUMO E1 enzyme and SUMO E3 ligase. It facilitates the attachment of SUMO proteins to target proteins which can influence protein stability localization and interaction with other proteins. This modification usually regulates important cellular functions such as transcription DNA repair and cell cycle progression.
Pathways
Proteins modified by UBE2I participate in significant biological pathways such as the DNA damage response and cell cycle regulation. In the DNA damage response UBE2I works with proteins such as p53 and BRCA1 to maintain genomic stability. In cell cycle pathways interactions with proteins like cyclin D1 and CDK inhibitors help control cellular proliferation by SUMOylating key regulatory proteins.
UBE2I has been implicated in cancer and neurodegenerative diseases. Altered SUMOylation by UBE2I can lead to the dysfunction of tumor suppressor proteins like p53 contributing to cancer development. In neurodegenerative diseases abnormal SUMOylation might affect proteins like tau which can lead to the progression of conditions such as Alzheimer's disease. The role of UBE2I in these disorders highlights it as a potential therapeutic target in addressing these conditions.